51
|
|
52
|
Green SP, Payne AD, Wheelhouse KM, Hallett JP, Miller PW, Bull JA. Diazo-Transfer Reagent 2-Azido-4,6-dimethoxy-1,3,5-triazine Displays Highly Exothermic Decomposition Comparable to Tosyl Azide. J Org Chem 2019; 84:5893-5898. [PMID: 30951630 DOI: 10.1021/acs.joc.9b00269] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
2-Azido-4,6-dimethoxy-1,3,5-triazine (ADT) was reported recently as a new "intrinsically safe" diazo-transfer reagent. This assessment was based on differential scanning calorimetry data indicating that ADT exhibits endothermic decomposition. We present DSC data on ADT that show exothermic decomposition with an initiation temperature ( Tinit) of 159 °C and an enthalpy of decomposition (Δ HD) of -1135 J g-1 (-207 kJ mol-1). We conclude that ADT is potentially explosive and must be treated with caution, being of comparable exothermic magnitude to tosyl azide (TsN3). A maximum recommended process temperature for ADT is 55 °C.
Collapse
Affiliation(s)
- Sebastian P Green
- Department of Chemistry, Molecular Sciences Research Hub , Imperial College London , White City Campus, 80 Wood Lane , London W12 0BZ , U.K.,Department of Chemical Engineering , Imperial College London , South Kensington Campus, Exhibition Road , London SW7 2AZ , U.K
| | - Andrew D Payne
- Process Safety, Pilot Plant Operations, GlaxoSmithKline , GSK Medicines Research Centre , Gunnels Wood Road , Stevenage , Hertfordshire SG1 2NY , U.K
| | - Katherine M Wheelhouse
- API Chemistry, Product Development & Supply, GlaxoSmithKline , GSK Medicines Research Centre , Gunnels Wood Road , Stevenage , Hertfordshire SG1 2NY , U.K
| | - Jason P Hallett
- Department of Chemical Engineering , Imperial College London , South Kensington Campus, Exhibition Road , London SW7 2AZ , U.K
| | - Philip W Miller
- Department of Chemistry, Molecular Sciences Research Hub , Imperial College London , White City Campus, 80 Wood Lane , London W12 0BZ , U.K
| | - James A Bull
- Department of Chemistry, Molecular Sciences Research Hub , Imperial College London , White City Campus, 80 Wood Lane , London W12 0BZ , U.K
| |
Collapse
|
53
|
Isidro-Llobet A, Kenworthy MN, Mukherjee S, Kopach ME, Wegner K, Gallou F, Smith AG, Roschangar F. Sustainability Challenges in Peptide Synthesis and Purification: From R&D to Production. J Org Chem 2019; 84:4615-4628. [PMID: 30900880 DOI: 10.1021/acs.joc.8b03001] [Citation(s) in RCA: 196] [Impact Index Per Article: 39.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
In recent years, there has been a growing interest in therapeutic peptides within the pharmaceutical industry with more than 50 peptide drugs on the market, approximately 170 in clinical trials, and >200 in preclinical development. However, the current state of the art in peptide synthesis involves primarily legacy technologies with use of large amounts of highly hazardous reagents and solvents and little focus on green chemistry and engineering. In 2016, the ACS Green Chemistry Institute Pharmaceutical Roundtable identified development of greener processes for peptide API as a critical unmet need, and as a result, a new Roundtable team formed to address this important area. The initial focus of this new team is to highlight best practices in peptide synthesis and encourage much needed innovations. In this Perspective, we aim to summarize the current challenges of peptide synthesis and purification in terms of sustainability, highlight possible solutions, and encourage synergies between academia, the pharmaceutical industry, and contract research organizations/contract manufacturing organizations.
Collapse
Affiliation(s)
- Albert Isidro-Llobet
- Medicines Research Centre , GlaxoSmithKline , Gunnels Wood Road , Stevenage SG1 2NY , U.K
| | - Martin N Kenworthy
- Pharmaceutical Technology and Development , AstraZeneca , Silk Road Business Park, Charter Way , Macclesfield SK10 2NA , U.K
| | - Subha Mukherjee
- Chemical and Synthetic Development , Bristol-Myers Squibb Company , One Squibb Drive , New Brunswick , New Jersey 08903 , United States
| | - Michael E Kopach
- Small Molecule Design and Development , Eli Lilly and Company , 1400 West Raymond Street , Indianapolis , Indiana , United States
| | - Katarzyna Wegner
- Active Pharmaceutical Ingredient Development , IPSEN Manufacturing Ireland, Ltd. , Blanchardstown Industrial Park , Dublin 15 , Ireland
| | - Fabrice Gallou
- Chemical & Analytical Development , Novartis , 4056 Basel , Switzerland
| | - Austin G Smith
- Drug Substance Process Development , Amgen, Inc. , 1 Amgen Center Drive , Thousand Oaks , California 91320 , United States
| | - Frank Roschangar
- Chemical Development , Boehringer Ingelheim Pharmaceuticals , Ridgefield , Connecticut 06877 , United States
| |
Collapse
|
54
|
Dugger R, Li B, Richardson P. Discovery and Development of Lorlatinib: A Macrocyclic Inhibitor of EML4-ALK for the Treatment of NSCLC. ACS SYMPOSIUM SERIES 2019. [DOI: 10.1021/bk-2019-1332.ch002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Affiliation(s)
- Robert Dugger
- Process Development, Medicinal Sciences, Chemical Research and Development, Pfizer Inc., Groton, Connecticut 06340, United States
| | - Bryan Li
- Process Development, Medicinal Sciences, Chemical Research and Development, Pfizer Inc., Groton, Connecticut 06340, United States
| | - Paul Richardson
- Oncology Medicinal Chemistry, Medicine Design, Pfizer Inc., La Jolla, California 92122, United States
| |
Collapse
|